112 related articles for article (PubMed ID: 8310712)
1. Analysis of imipramine and three metabolites produced by isozyme CYP2D6 expressed in a human cell line.
Su P; Coutts RT; Baker GB; Daneshtalab M
Xenobiotica; 1993 Nov; 23(11):1289-98. PubMed ID: 8310712
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of imipramine in vitro by isozyme CYP2D6 expressed in a human cell line, and observations on metabolite stability.
Coutts RT; Su P; Baker GB; Daneshtalab M
J Chromatogr; 1993 Jun; 615(2):265-72. PubMed ID: 8335704
[TBL] [Abstract][Full Text] [Related]
3. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine.
Brøsen K; Zeugin T; Meyer UA
Clin Pharmacol Ther; 1991 Jun; 49(6):609-17. PubMed ID: 2060250
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of trimipramine in vitro by human CYP2D6 isozyme.
Bolaji OO; Coutts RT; Baker GB
Res Commun Chem Pathol Pharmacol; 1993 Oct; 82(1):111-20. PubMed ID: 8272570
[TBL] [Abstract][Full Text] [Related]
5. The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation.
Chiba K; Saitoh A; Koyama E; Tani M; Hayashi M; Ishizaki T
Br J Clin Pharmacol; 1994 Mar; 37(3):237-42. PubMed ID: 8198931
[TBL] [Abstract][Full Text] [Related]
6. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
Madsen H; Nielsen KK; Brøsen K
Br J Clin Pharmacol; 1995 Apr; 39(4):433-9. PubMed ID: 7640151
[TBL] [Abstract][Full Text] [Related]
7. Comparison of catalytical activity and stereoselectivity between the recombinant human cytochrome P450 2D6.1 and 2D6.10.
Kong LM; Qian MR; Hu HH; Xu SY; Yu LS; Jiang HD; Chen SQ; Zeng S
Pharmazie; 2012 May; 67(5):440-7. PubMed ID: 22764579
[TBL] [Abstract][Full Text] [Related]
8. Studies on cytochrome P450 responsible for oxidative metabolism of imipramine in human liver microsomes.
Ohmori S; Takeda S; Rikihisa T; Kiuchi M; Kanakubo Y; Kitada M
Biol Pharm Bull; 1993 Jun; 16(6):571-5. PubMed ID: 8364509
[TBL] [Abstract][Full Text] [Related]
9. Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (s)-fluoxetine, and N-desmethyldiltiazem.
Hanson KL; VandenBrink BM; Babu KN; Allen KE; Nelson WL; Kunze KL
Drug Metab Dispos; 2010 Jun; 38(6):963-72. PubMed ID: 20200233
[TBL] [Abstract][Full Text] [Related]
10. Parallel pathway interactions in imipramine metabolism in rats.
Chiba M; Fujita S; Suzuki T
J Pharm Sci; 1988 Nov; 77(11):944-7. PubMed ID: 3225754
[TBL] [Abstract][Full Text] [Related]
11. Isolation of partially purified P450 2D18 and characterization of activity toward the tricyclic antidepressants imipramine and desipramine.
Thompson CM; Kawashima H; Strobel HW
Arch Biochem Biophys; 1998 Nov; 359(1):115-21. PubMed ID: 9799568
[TBL] [Abstract][Full Text] [Related]
12. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.
Brøsen K; Otton SV; Gram LF
Clin Pharmacol Ther; 1986 Nov; 40(5):543-9. PubMed ID: 3769385
[TBL] [Abstract][Full Text] [Related]
13. Determination of imipramine, desipramine and their hydroxy metabolites by reversed-phase chromatography with ultraviolet and coulometric detection.
Foglia JP; Sorisio D; Perel JM
J Chromatogr; 1991 Dec; 572(1-2):247-58. PubMed ID: 1818058
[TBL] [Abstract][Full Text] [Related]
14. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver.
Lemoine A; Gautier JC; Azoulay D; Kiffel L; Belloc C; Guengerich FP; Maurel P; Beaune P; Leroux JP
Mol Pharmacol; 1993 May; 43(5):827-32. PubMed ID: 8502233
[TBL] [Abstract][Full Text] [Related]
15. Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine.
Hermann DJ; Krol TF; Dukes GE; Hussey EK; Danis M; Han YH; Powell JR; Hak LJ
J Clin Pharmacol; 1992 Feb; 32(2):176-83. PubMed ID: 1613128
[TBL] [Abstract][Full Text] [Related]
16. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.
Skjelbo E; Brøsen K; Hallas J; Gram LF
Clin Pharmacol Ther; 1991 Jan; 49(1):18-23. PubMed ID: 1988236
[TBL] [Abstract][Full Text] [Related]
17. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine.
Brøsen K; Gram LF
Eur J Clin Pharmacol; 1989; 37(2):155-60. PubMed ID: 2792169
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous high-performance liquid chromatography-electrochemical detection determination of imipramine, desipramine, their 2-hydroxylated metabolites, and imipramine N-oxide in human plasma and urine: preliminary application to oxidation pharmacogenetics.
Koyama E; Kikuchi Y; Echizen H; Chiba K; Ishizaki T
Ther Drug Monit; 1993 Jun; 15(3):224-35. PubMed ID: 8333003
[TBL] [Abstract][Full Text] [Related]
19. Active metabolites of imipramine and desipramine in man.
Potter WZ; Calil HM; Sutfin TA; Zavadil AP; Jusko WJ; Rapoport J; Goodwin FK
Clin Pharmacol Ther; 1982 Mar; 31(3):393-401. PubMed ID: 7060321
[TBL] [Abstract][Full Text] [Related]
20. Quantitative mapping of metabolites of imipramine and desipramine in plasma samples by gas chromatographic-mass spectrometry.
Narasimhachari N; Saady J; Friedel RO
Biol Psychiatry; 1981 Oct; 16(10):937-44. PubMed ID: 7306616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
